CORONA Remedies Reports Strong Q2FY27 Results Outpacing Indian Pharma Market Growth
Corona Remedies Ltd · Press Release · 31 Oct 2026, 12:16 am
CORONA Remedies Reports Strong Q2FY27 Results Outpacing Indian Pharma Market Growth CORONA Remedies reported 22.2% YoY revenue growth to ₹441.2 Cr in Q2FY27, outpacing IPM growth by 1.9x for MAT Sep'26. EBITDA rose 22.3% YoY to ₹96.0 Cr with stable margins at 21.7%, while PAT increased 15.3% YoY to ₹60.3 Cr, impacted by higher depreciation and amortization from newly commissioned facilities and brand acquisitions. Chronic and semi-chronic therapies contributed 71.2% to revenue. Additionally, the company secured Brazil's ANVISA GMP certification for its Bhayla facility covering oral solids and women's hormone production lines.
Original exchange filing (PDF)
More announcements from Corona Remedies Ltd
- Intimation of Participation in Analyst / Investor Conference · 16 Nov 2026
- Intimation of Participation in Analyst / Investor Conference · 07 Nov 2026
- Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the second quarter and half year ended September 30, 2026 · 05 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- Audio Recording of Q2H1FY27 Earnings Conference Call with Analysts / Investors · 02 Nov 2026
- Intimation for Analyst / Investor Meet · 31 Oct 2026
- Analyst / Investor Presentation · 31 Oct 2026
- Unaudited Financial Results along with the Limited Review Reports for the second quarter and half year ended September 30, 2026 · 31 Oct 2026
